Registration Options

Activity Dates: 04/27/2022 - 04/27/2025

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

A 2021 report estimates 6.2 million Americans age 65 and older have Alzheimer’s Disease (AD). Estimates predict this population could grow to 13.8 million by 2060 if no medical developments are made to prevent, slow, or cure AD. Furthermore, Alzheimer’s is the 6th leading cause of death in the US; while deaths from stroke, heart disease and HIV decreased between 2000-2019, deaths due to AD increased more than 145%. Currently available treatment options may modestly slow cognitive decline. Several medications are additionally used off label for psychosis and other behavioral and psychological symptoms of dementia; recently the Food and Drug Administration (FDA) rejected an application for one agent (pimavanserin) to receive FDA approval for this indication. More recently, aducanumab was approved using an accelerated process based on reducing amyloid beta plaque, a surrogate marker for AD. This approval has been met with controversy that impacts how AD is treated and may impact FDA approval for other agents in the future.


Course Requirements

To receive ACPE credit for this session, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information and Disclosures

Learning Objectives

  1. Describe current options for the treatment of Alzheimer’s Disease.
  2. Discuss the history of drug design focusing on amyloid plaque reduction.
  3. Review data leading to the Food and Drug Administration approval of aducanumab.
  4. Identify the potential use of aducanumab in individualized patient cases.

Continuing Education Credit and Disclosures

Activity Dates: 04/27/2022 - 04/27/2025
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-052-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.